000 01138 a2200325 4500
005 20250512212907.0
264 0 _c19830811
008 198308s 0 0 eng d
022 _a0077-0094
024 7 _a10.1159/000407518
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aStern, G M
245 0 0 _aClinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
_h[electronic resource]
260 _bModern problems of pharmacopsychiatry
_c1983
300 _a215-9 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article
650 0 4 _aAmphetamine
_xpharmacology
650 0 4 _aClinical Trials as Topic
650 0 4 _aDouble-Blind Method
650 0 4 _aHumans
650 0 4 _aHydrogen-Ion Concentration
650 0 4 _aParkinson Disease
_xdrug therapy
650 0 4 _aPhenethylamines
_xtherapeutic use
650 0 4 _aSelegiline
_xtherapeutic use
700 1 _aLees, A J
700 1 _aHardie, R
700 1 _aSandler, M
773 0 _tModern problems of pharmacopsychiatry
_gvol. 19
_gp. 215-9
856 4 0 _uhttps://doi.org/10.1159/000407518
_zAvailable from publisher's website
999 _c6408295
_d6408295